913625-36-2 Usage
Derivative of propylamine and 3-hydroxypropylamine
This compound is derived from two simpler amines, propylamine, and 3-hydroxypropylamine, indicating its structure is built upon these basic frameworks.
Benzyloxycarbonyl group attachment
The amino group in this compound is attached to a benzyloxycarbonyl group, which influences its reactivity and properties.
Protective group for amine
The benzyloxycarbonyl group serves as a protective group for the amine group, allowing for selective reactions at other sites on the molecule. This means that the compound can undergo reactions without affecting the amine functionality.
3-Hydroxypropyl group
The presence of a 3-hydroxypropyl group in the compound provides potential for interactions with other molecules in biological systems. This hydroxyl group can form hydrogen bonds and participate in other interactions, making it an important functional group for biological activity.
Use in organic synthesis and pharmaceutical research
2-(S)-2-(benzyloxycarbonyl)amino-N-(3-hydroxypropyl)propylamine is used as a building block in organic synthesis and pharmaceutical research, particularly in the development of potential medications.
Importance as a building block
This compound represents an important building block in chemical and pharmaceutical research due to its diverse range of potential uses and its ability to be incorporated into more complex molecules.
Check Digit Verification of cas no
The CAS Registry Mumber 913625-36-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,3,6,2 and 5 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 913625-36:
(8*9)+(7*1)+(6*3)+(5*6)+(4*2)+(3*5)+(2*3)+(1*6)=162
162 % 10 = 2
So 913625-36-2 is a valid CAS Registry Number.
913625-36-2Relevant articles and documents
IOP-lowering effect of isoquinoline-5-sulfonamide compounds in ocular normotensive monkeys
Sumi, Kengo,Inoue, Yoshihiro,Nishio, Masahiro,Naito, Yasuhito,Hosoya, Takamitsu,Suzuki, Masaaki,Hidaka, Hiroyoshi
, p. 831 - 834 (2014/02/14)
Rho-associated coiled coil-formed protein kinase (ROCK) inhibitors are under development as a new class of antiglaucoma agents. Based on the potent ROCK inhibitor H-1152, previously developed by us, we explored the possibility of related compounds as anti
4-haloisoquinoline derivative and drug containing the same
-
Page/Page column 4, (2010/11/26)
The present invention relates to compounds which have a potent Rho-kinase inhibitory action and which are useful as therapeutic agents for treating diseases, such as hypertension, pulmonary hypertension, cerebral vasospasm, angina pectoris, cardiac failur
